Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).

Darren R. Feldman; James Hu; Sandy Srinivas; Walter Michael Stadler; Brian Addis Costello; Leonard Joseph Appleman; Matthew I. Milowsky; Sujata Patil; Maria Bromberg; Patrick Nolan; Tanya B. Dorff; Victor E. Reuter; Hikmat Al-Ahmadie; Samuel Funt; Dean F. Bajorin; George J. Bosl; David I. Quinn; Robert J. Motzer

doi:10.1200/jco.2018.36.15_suppl.4508

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.4508 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 4508-4508 ◽

Cited By ~ 6

Author(s):

Darren R. Feldman ◽

James Hu ◽

Sandy Srinivas ◽

Walter Michael Stadler ◽

Brian Addis Costello ◽

...

Keyword(s):

Germ Cell ◽

Germ Cell Tumors ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Poor Risk ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

A Multi-Institutional Randomized Phase 2 Trial of the Oncolytic Virus Reolysin in the First Line Treatment Metastatic Adenocarcinoma of the Pancreas (Map)

Annals of Oncology ◽

10.1093/annonc/mdu438.19 ◽

2014 ◽

Vol 25 ◽

pp. v1 ◽

Cited By ~ 5

Author(s):

T. Bekaii-Saab ◽

A.M. Noonan ◽

G. Lesinski ◽

S. Mikhail ◽

K. Ciombor ◽

...

Keyword(s):

Oncolytic Virus ◽

Line Treatment ◽

Metastatic Adenocarcinoma ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Adenocarcinoma Of The Pancreas ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

Cisplatin and gemcitabine plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase 2 trial

Annals of Oncology ◽

10.1093/annonc/mdw371.104 ◽

2016 ◽

Vol 27 ◽

pp. vi240 ◽

Cited By ~ 3

Author(s):

J.W. Valle ◽

N. Bousmans ◽

W. Zhang ◽

R.A. Walgren ◽

A. Vogel

Keyword(s):

Biliary Tract ◽

Biliary Tract Cancer ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Double Blind ◽

Tract Cancer ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial

Cancer ◽

10.1002/cncr.29229 ◽

2015 ◽

Vol 121 (10) ◽

pp. 1654-1661 ◽

Cited By ~ 22

Author(s):

John D. Hainsworth ◽

Gedske Daugaard ◽

Thierry Lesimple ◽

Gerdt Hübner ◽

F. Anthony Greco ◽

...

Keyword(s):

Primary Site ◽

Unknown Primary ◽

Line Treatment ◽

Phase 2 ◽

Unknown Primary Site ◽

First Line ◽

Carcinoma Of Unknown Primary ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

Disrupt: A Randomized Phase 2 Trial of Ombrabulin (AVE8062) Combined with a Taxane-Platinum Regimen in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

Annals of Oncology ◽

10.1016/s0923-7534(20)33843-6 ◽

2012 ◽

Vol 23 ◽

pp. ix410

Author(s):

J. von Pawel ◽

V. Gorbounova ◽

M. Reck ◽

D. Kowalski ◽

A. Allard ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

5060 POSTER Albumin-bound Paclitaxel (ab-pac) Versus Docetaxel for First-line Treatment of Metastatic Breast Cancer (MBC): Overall Survival (OS) Subset Analyses of a Randomized Phase 2 Trial

European Journal of Cancer ◽

10.1016/s0959-8049(11)71502-7 ◽

2011 ◽

Vol 47 ◽

pp. S348

Author(s):

W.J. Gradishar ◽

D.A. Krasnojon ◽

S.V. Cheporov ◽

A.N. Makhson ◽

G.M. Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

Re: Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients with Intermediate- or Poor-Risk Germ Cell Tumors

The Journal of Urology ◽

10.1016/j.juro.2017.05.023 ◽

2017 ◽

Vol 198 (2) ◽

pp. 257-257

Author(s):

Jerome P. Richie

Keyword(s):

Germ Cell ◽

Germ Cell Tumors ◽

Line Treatment ◽

First Line ◽

Poor Risk ◽

First Line Treatment

Download Full-text

Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.610 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 610-610 ◽

Cited By ~ 3

Author(s):

Ahmad Awada ◽

Ramon Colomer ◽

Igor Bondarenko ◽

Kenichi Inoue ◽

Rajendra A. Badwe ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

DISRUPT: A randomized phase 2 trial of ombrabulin (AVE8062) combined with a taxane-platinum regimen in the first-line treatment of metastatic non-small cell lung cancer (NSCLC)

Pneumologie ◽

10.1055/s-0033-1334708 ◽

2013 ◽

Vol 67 (S 01) ◽

Author(s):

J von Pawel ◽

V Gorbounova ◽

M Reck ◽

DM Kowalski ◽

A Allard ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial

Cancer ◽

10.1002/cncr.29893 ◽

2016 ◽

Vol 122 (7) ◽

pp. 1050-1059 ◽

Cited By ~ 23

Author(s):

Masayuki Takeda ◽

Takeharu Yamanaka ◽

Takashi Seto ◽

Hidetoshi Hayashi ◽

Koichi Azuma ◽

...

Keyword(s):

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Oncology Group ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text